Actively Recruiting

Age: 45Years +
All Genders
NCT06595134

AI-POD Clinical Validation Study for Obese Patients

Led by University Hospital, Bonn · Updated on 2024-09-19

1200

Participants Needed

6

Research Sites

208 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Bonn

Lead Sponsor

E

European Union

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study is aimed at patients who suffer from severe obesity and receive a computerised tomography (CT) scan of the heart. A total of 1200 patients across Europe are to take part in the study. It is a multi-centre, controlled, open, randomised study. As part of the study, a citizen app will be installed on a smartphone for randomly selected study participants. A fitness tracker will also be issued so that certain parameters, such as heart rate and daily number of steps, can be recorded.

CONDITIONS

Official Title

AI-POD Clinical Validation Study for Obese Patients

Who Can Participate

Age: 45Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 45 years or older at the time of consent
  • Body mass index (BMI) of 30 kg/m2 or higher
  • Suspected cardiovascular disease with more than 15% pretest probability according to ESC guidelines
  • Scheduled for cardiac CT examinations including coronary calcium scoring and coronary CT angiography
  • Provided informed consent to participate
Not Eligible

You will not qualify if you...

  • Experienced myocardial infarction, stroke, unstable angina, transient ischemic attack, or hospitalization due to heart failure within 2 months before inclusion
  • Planned coronary, carotid, or peripheral artery revascularisation known at inclusion
  • Classified as NYHA class IV heart failure
  • Uncontrolled diabetes with HbA1c 11% or higher at inclusion
  • Uncontrolled hypertension with systolic blood pressure 160 mmHg or higher and/or diastolic blood pressure 100 mmHg or higher at inclusion
  • Severe renal impairment with eGFR less than 30 mL/min/1.73 m2 at inclusion
  • Alanine aminotransferase (ALT) or alkaline phosphatase (APT) levels greater than 3 times the upper limit of normal
  • Total bilirubin level greater than 1.5 times the upper limit of normal
  • History of active or untreated malignancy or remission from significant malignancy less than 5 years
  • Previous organ transplantation or awaiting organ transplant
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Medical University Vienna

Vienna, Austria, 1090

Not Yet Recruiting

2

University Hospital Leuven

Leuven, Belgium, 3000

Not Yet Recruiting

3

University Hospital Pilsen

Pilsen, Czechia, 323 00

Actively Recruiting

4

University Hospital Bonn

Bonn, North Rhine-Westphalia, Germany, 53127

Actively Recruiting

5

University Hospital Mannheim

Mannheim, Germany, 68167

Actively Recruiting

6

University Hospital Zürich

Zurich, Switzerland, 8091

Not Yet Recruiting

Loading map...

Research Team

U

Ulrike Attenberger, Prof. Dr.

CONTACT

W

Wiebke Fenske, Prof. Dr.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here